M. Attias

Co-Targeting Luminal B Breast Cancer with S-Adenosylmethionine and Immune Checkpoint Inhibitor Reduces Primary Tumor Growth and Progression, and Metastasis to Lungs and Bone

M. Szyf, S. Rabbani, C. Piccirillo, 2022, Cancers.

Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates anti-tumor immune responses.

N. Sonenberg, W. Miller, Jie Su, 2021, The Journal of clinical investigation.

The MNK1/2-eIF4E axis drives melanoma plasticity, progression, and resistance to immunotherapy

N. Sonenberg, W. Miller, Jie Su, 2020, bioRxiv.

S-adenosylmethionine blocks tumorigenesis and with immune checkpoint inhibitor enhances anti-cancer efficacy against BRAF mutant and wildtype melanomas

M. Szyf, S. Rabbani, C. Piccirillo, 2023, Neoplasia.

Mechanisms of human FoxP3+ Treg cell development and function in health and disease

C. Piccirillo, M. Attias, T. Al-Aubodah, 2019, Clinical and experimental immunology.

Enhanced Anticancer Effect of a Combination of S-adenosylmethionine (SAM) and Immune Checkpoint Inhibitor (ICPi) in a Syngeneic Mouse Model of Advanced Melanoma

M. Szyf, S. Rabbani, C. Piccirillo, 2020, Frontiers in Oncology.

Materno-Fetal Transfer of Preproinsulin Through the Neonatal Fc Receptor Prevents Autoimmune Diabetes

N. Gupta, S. Justesen, S. Buus, 2015, Diabetes.

The impact of Foxp3+ regulatory T-cells on CD8+ T-cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors.

C. Piccirillo, M. Attias, 2024, British journal of pharmacology.